Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 5.9%

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shot up 5.9% during mid-day trading on Wednesday . The stock traded as high as $124.37 and last traded at $124.01. 550,813 shares traded hands during trading, a decline of 43% from the average session volume of 972,684 shares. The stock had previously closed at $117.12.

Analysts Set New Price Targets

A number of brokerages have weighed in on SRPT. Evercore ISI boosted their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a research note on Tuesday, February 20th. Royal Bank of Canada lifted their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. Wedbush reiterated an “outperform” rating and set a $224.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. TheStreet upgraded shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $158.38.

Sarepta Therapeutics Stock Performance

The company has a 50-day moving average price of $126.18 and a two-hundred day moving average price of $110.21. The stock has a market capitalization of $11.67 billion, a P/E ratio of -20.30 and a beta of 0.94. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The company had revenue of $396.80 million for the quarter, compared to analysts’ expectations of $387.18 million. During the same period in the prior year, the business earned ($1.24) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 53.6% compared to the same quarter last year. Equities analysts expect that Sarepta Therapeutics, Inc. will post 2.13 earnings per share for the current year.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the sale, the director now owns 22,840 shares of the company’s stock, valued at $2,815,030. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $123.25, for a total value of $1,848,750.00. Following the completion of the sale, the director now owns 22,840 shares of the company’s stock, valued at $2,815,030. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stephen Mayo sold 3,135 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $122.96, for a total value of $385,479.60. Following the completion of the sale, the director now directly owns 6,621 shares of the company’s stock, valued at approximately $814,118.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,096 shares of company stock valued at $2,739,419. 7.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Assenagon Asset Management S.A. increased its holdings in shares of Sarepta Therapeutics by 14.0% during the first quarter. Assenagon Asset Management S.A. now owns 437,690 shares of the biotechnology company’s stock valued at $56,663,000 after acquiring an additional 53,911 shares in the last quarter. PFG Investments LLC lifted its position in shares of Sarepta Therapeutics by 23.7% during the 1st quarter. PFG Investments LLC now owns 24,095 shares of the biotechnology company’s stock valued at $3,119,000 after buying an additional 4,610 shares in the last quarter. Altfest L J & Co. Inc. purchased a new position in shares of Sarepta Therapeutics during the 1st quarter valued at about $348,000. Hudson Capital Management LLC purchased a new position in shares of Sarepta Therapeutics during the 1st quarter valued at about $220,000. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Sarepta Therapeutics by 100.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,996 shares of the biotechnology company’s stock valued at $647,000 after buying an additional 2,504 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.